Compare Mongodb Inc (MDB) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance

MDB trades at $356.29, down 6.56% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly EPS beats, with Q3 2026 results pending. Revenue has grown from $874 million in 2022 to $2.01 billion in 2025, though net losses persist, narrowing to -$129 million in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.

The outlook is cautiously optimistic, with a consensus price target of $456.76 implying 28% upside. Key opportunities include raised long-term revenue targets exceeding 20% growth and AI-driven product expansion. Risks involve continued net losses, high valuation multiples, and execution challenges amid leadership changes. Analyst consensus is strongly bullish with 80% buy ratings, but stock volatility may persist near-term.

Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.

The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.